_ OUR NEWS
OCULUS BIOMED NEWS
July 30, 2023
Bio-Asia Taiwan is Asia’s largest biotech conference and networking event. OBM was invited by the Australian Government Trade Arm – Austrade to present at this event. OBM […]
July 1, 2023
We are delighted to welcome Robyn to the OBM Scientific Board. She brings significant experience and currency to the company. Background profile follows: Professor Robyn Guymer […]
May 24, 2023
OBM was represented by its CEO & CSO. This was OBM’s first formal representation at an industry conference which included valuable one-on-one private meetings with industry […]
February 22, 2022
Oculus Biomed Limited (“OBM”) is pleased to announce that the research data which covers OBM’s OBM-1701, its leading drug candidate for the treatment of wet-AMD, has […]
October 5, 2021
Oculus Biomed Limited (“OBM”) is pleased to announce that it has entered an Agreement with Centre for Eye Research Australia (“CERA”), in Melbourne, Victoria State, Australia. […]
June 11, 2021
Oculus Biomed Limited (“OBM”) is pleased to announce the grant of the Chinese Patent which covers the OBM-1701, OBM’s leading novel drug candidate for treating wet-type […]